A multicenter, open-label, long-term extension safety and efficacy study of filgotinib treatment in subjects with moderately to severely active psoriatic arthritis
Latest Information Update: 22 Apr 2022
At a glance
- Drugs Filgotinib (Primary)
- Indications Psoriatic arthritis
- Focus Adverse reactions
- Acronyms EQUATOR 2
- Sponsors Galapagos NV
- 05 Jun 2021 Results of a post hoc analysis assessing the effect of Filgotinib on Enthesitis at 100-Week presented at the 22nd Annual Congress of the European League Against Rheumatism
- 05 Jun 2021 Results of a post-hoc analysis from EQUATOR and EQUATOR 2 (up to OLE week 100) assessing effect of Filgotinib on individual PASDAS socre components and association between PASDAS disease activity levels presented at the 22nd Annual Congress of the European League Against Rheumatism
- 05 Jun 2021 Results post-hoc analysis from clinical studies: EQUATOR and EQUATOR 2 assessing patient-level correlation between changes over time in three PsA clinical disease domains of skin, joint and enthesitis presented at the 22nd Annual Congress of the European League Against Rheumatism